Sirolimus loaded polyol modified liposomes for the treatment of Posterior Segment Eye Diseases

Suri, Reshal; Neupane, Yub Raj; Mehra, Nikita; Jain, Gaurav; Kohli, Kanchan

doi:10.1016/j.mehy.2019.109518

Cited by 20 publications

(8 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the current research, available eye disease therapies are still associated with side effects and remain not fully effective. As such, there is an ongoing need to develop new therapeutic options for the treatment of ocular disorders [193,194]. As noted in the third part of this paper, MMP and TIMP expression and activity could be an attractive pharmacological target and any modulation may significantly limit the development and progression of eye diseases.…”

Section: Novel Agents Modulating the Expression And Activity Of Mmps ...mentioning

confidence: 95%

The Role of Metalloproteinases and Their Tissue Inhibitors on Ocular Diseases: Focusing on Potential Mechanisms

Caban

Owczarek

Lewandowska

2022

IJMS

View full text Add to dashboard Cite

Eye diseases are associated with visual impairment, reduced quality of life, and may even lead to vision loss. The efficacy of available treatment of eye diseases is not satisfactory. The unique environment of the eye related to anatomical and physiological barriers and constraints limits the bioavailability of existing agents. In turn, complex ethiopathogenesis of ocular disorders that used drugs generally are non-disease specific and do not act causally. Therefore, there is a need for the development of a new therapeutic and preventive approach. It seems that matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) have a significant role in the development and progression of eye diseases and could be used in the therapy of these disorders as pharmacological targets. MMPs and TIMPs play an important role in the angiogenesis, epithelial-mesenchymal transition, cell invasion, and migration, which occur in ocular diseases. In this review, we aim to describe the participation of MMPs and TIMPs in the eye diseases, such as age-related macular degeneration, cataract, diabetic retinopathy, dry eye syndrome, glaucoma, and ocular cancers, posterior capsule opacification focusing on potential mechanisms.

show abstract

Section: Novel Agents Modulating the Expression And Activity Of Mmps ...mentioning

confidence: 95%

The Role of Metalloproteinases and Their Tissue Inhibitors on Ocular Diseases: Focusing on Potential Mechanisms

Caban

Owczarek

Lewandowska

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Various modifications can be made onto the surface of liposomes and drug release can be controlled by changing the composition of the lipid bilayer. Suri et al (2020) [ 86 ] proposed to incorporate edge activators (polyol) in the liposomal bilayer in conventional liposomes that are inefficient to shuttle the cargo to the posterior segment of the eye to enhance the liposomal fluidity and deformability. In this way, polyol-modified liposomes would successfully penetrate the blood retinal barrier and would efficiently shuttle the drug sirolimus to the posterior segment of the eye making this a promising strategy for the treatment of posterior segment eye diseases.…”

Section: Drug Delivery Systems Proposed For Amdmentioning

confidence: 99%

Therapeutic Approaches for Age-Related Macular Degeneration

Galindo

Blanco-Llamero

Ana

et al. 2022

IJMS

View full text Add to dashboard Cite

Damage to the retinal pigment epithelium, Bruch’s membrane and/or tissues underlying macula is known to increase the risk of age-related macular degeneration (AMD). AMD is commonly categorized in two distinct types, namely, the nonexudative (dry form) and the exudative (wet form). Currently, there is no ideal treatment available for AMD. Recommended standard treatments are based on the use of vascular endothelial growth factor (VEGF), with the disadvantage of requiring repeated intravitreal injections which hinder patient’s compliance to the therapy. In recent years, several synthetic and natural active compounds have been proposed as innovative therapeutic strategies against this disease. There is a growing interest in the development of formulations based on nanotechnology because of its important role in the management of posterior eye segment disorders, without the use of intravitreal injections, and furthermore, with the potential to prolong drug release and thus reduce adverse effects. In the same way, 3D bioprinting constitutes an alternative to regeneration therapies for the human retina to restore its functions. The application of 3D bioprinting may change the current and future perspectives of the treatment of patients with AMD, especially those who do not respond to conventional treatment. To monitor the progress of AMD treatment and disease, retinal images are used. In this work, we revised the recent challenges encountered in the treatment of different forms of AMD, innovative nanoformulations, 3D bioprinting, and techniques to monitor the progress.

show abstract

“…In eye diseases of the posterior segment, ordinary liposomes cannot cross anatomical and physiological barriers. Therefore, liposomes modified by polyhydroxy compounds are characterized with high stability and mobility and can be used to deliver drugs to the posterior segment (Suri, Neupane et al, 2020). Moreover, liposomes encapsulated with ciprofloxacin increased the bioavailability of ciprofloxacin (Feghhi, Sharif Makhmalzadeh et al, 2020), which provides new technical support for the treatment of endophthalmitis.…”

Section: Liposomesmentioning

confidence: 99%

Nanoparticles in ocular applications and their potential toxicity

Cao

Yang

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Nanotechnology has been developed rapidly in recent decades and widely applied in ocular disease therapy. Nano-drug delivery systems overcome the bottlenecks of current ophthalmic drug delivery and are characterized with strong biocompatibility, stability, efficiency, sustainability, controllability, and few side effects. Nanoparticles have been identified as a promising and generally safe ophthalmic drug-delivery system based on the toxicity assessment in animals. Previous studies have found that common nanoparticles can be toxic to the cornea, conjunctiva, and retina under certain conditions. Because of the species differences between humans and animals, advanced in vitro cell culture techniques, such as human organoids, can mimic the human organism to a certain extent, bringing nanoparticle toxicity assessment to a new stage. This review summarizes the advanced application of nanoparticles in ocular drug delivery and the potential toxicity, as well as some of the current challenges and future opportunities in nanotoxicological evaluation.

show abstract

Sirolimus loaded polyol modified liposomes for the treatment of Posterior Segment Eye Diseases

Cited by 20 publications

References 55 publications

The Role of Metalloproteinases and Their Tissue Inhibitors on Ocular Diseases: Focusing on Potential Mechanisms

The Role of Metalloproteinases and Their Tissue Inhibitors on Ocular Diseases: Focusing on Potential Mechanisms

Therapeutic Approaches for Age-Related Macular Degeneration

Nanoparticles in ocular applications and their potential toxicity

Contact Info

Product

Resources

About